TEDIZ 200mg TAB 6s

Description

Sivextro (Tedizolid Phosphate) 200 mg Film-Coated Tablets

Sivextro is an antibiotic medication containing tedizolid phosphate, a second-generation oxazolidinone-class antibacterial agent. It is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and adolescents aged 12 years and older.

🧪 Mechanism of Action

Tedizolid phosphate is a prodrug that, once administered, is converted to its active form, tedizolid. Tedizolid exerts its antibacterial effect by binding to the 50S subunit of the bacterial ribosome, thereby inhibiting protein synthesis. This mechanism is distinct from other non-oxazolidinone antibiotics, which may reduce the likelihood of cross-resistance.

💊 Dosage and Administration

• Recommended Dosage: 200 mg once daily for 6 days.
• Administration: Can be taken orally with or without food.
• Switching Between Forms: Patients may switch from intravenous to oral administration when clinically appropriate, as no dose adjustment is necessary.

🦠 Spectrum of Activity

Tedizolid is effective against a range of Gram-positive bacteria, including:

• Staphylococcus aureus (both methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] strains)
• Streptococcus pyogenes
• Streptococcus agalactiae
• Streptococcus anginosus group (comprising S. anginosus, S. intermedius, and S. constellatus)
• Enterococcus faecalis

This broad spectrum makes it a valuable option for treating ABSSSI caused by susceptible organisms .

⚠️ Warnings and Precautions

Before initiating treatment with Silvestro, consider the following:

• Allergy: Do not use if allergic to tedizolid phosphate or any other component of the tablet.
• Drug Interactions: Tedizolid is a reversible inhibitor of monoamine oxidase (MAO). Caution is advised when co-administering with MAO inhibitors or serotonergic agents.
• Diarrhea: Monitor for signs of Clostridium difficile-associated diarrhea, which can occur during or after treatment.
• Platelet Count: Patients with a history of bleeding or low platelet counts should be monitored closely .

📈 Efficacy

Clinical trials have demonstrated that a 6-day regimen of 200 mg once daily of tedizolid phosphate is noninferior to a 10-day regimen of 600 mg every 12 hours of linezolid for the treatment of ABSSSI. This suggests that tedizolid phosphate offers a shorter treatment duration with comparable efficacy.

🛡️ Safety Profile

Common side effects may include nausea, headache, diarrhea, and dizziness. Serious adverse reactions are less common but can include severe diarrhea or signs of blood disorders. Patients should be advised to report any unusual symptoms promptly.

For more detailed information, including contraindications and full prescribing information, please refer to the or consult with a healthcare professional.